Requires certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale.
Summary
Bill A07142 aims to amend the insurance law and the public health law in New York to require health insurance issuers to ensure that at least 85% of prescription drug rebates are passed on to patients at the point of sale. This legislation seeks to enhance transparency in the pricing of prescription drugs and reduce out-of-pocket costs for consumers by mandating that insurers calculate defined cost sharing based on the reduced price reflecting these rebates. Insurers must also submit annual certifications to the superintendent to confirm compliance with this requirement.
The bill introduces definitions for key terms such as 'defined cost sharing,' 'rebate,' and 'price protection rebate,' which clarify the obligations of insurers regarding the management of rebates. By enforcing that a significant portion of rebates is reflected in the cost sharing at the point of sale, the bill aims to alleviate the financial burden on patients when purchasing prescription medications. The legislation is set to take effect immediately for contracts issued, renewed, or amended on or after January 1, 2025.
Impact
If enacted, Bill A07142 will significantly alter the landscape of prescription drug pricing in New York. It will require health insurance issuers to adjust their pricing structures to ensure that a majority of rebates are directly benefiting patients, potentially leading to lower out-of-pocket costs for consumers. This change may also prompt insurers to negotiate more favorable rebate agreements with pharmaceutical companies, as they will need to pass these savings on to their enrollees. The bill's provisions will also enhance the accountability of insurers in reporting their rebate practices to the state.
Sentiment
The sentiment surrounding Bill A07142 appears to be generally positive among advocates for consumer rights and healthcare affordability. Supporters argue that the bill is a necessary step towards making prescription drugs more affordable for patients. However, there may be concerns from some insurance companies regarding the administrative burden of compliance and the potential impact on their financial models. The lack of recorded votes or committee discussions at this stage indicates that the bill is still in early consideration.
Contention
Notable points of contention may arise from insurance companies that could be concerned about the implications of the bill on their profitability and operational processes. Insurers may argue that the requirement to pass through a significant portion of rebates could impact their ability to negotiate effectively with drug manufacturers. Additionally, the confidentiality provisions regarding rebate disclosures might lead to debates about transparency and the public's right to know about drug pricing practices.
Same As
Requires certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale.
Requires certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale.
Requires certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale.